BSD Medical Hires Luis Lopes to Support Terumo Europe NV’s Sales and Marketing Team

BSD Medical Corporation (NASDAQ:BSDM) (Company or BSD) (www.BSDMedical.com), a leading provider of medical systems that treat cancer and benign diseases using heat therapy, today announced that Luis Lopes has joined BSD Medical to support Terumo Europe NV’s (Terumo) sales and marketing team. Mr. Lopes will provide technical, educational and field support for BSD’s MicroThermX® Microwave Ablation System during Terumo’s continued, strategic rollout. Mr. Lopes will also lead educational and training activities with customers and sales representatives throughout Europe. BSD’s exclusive, multi-million dollar agreement with Terumo covers distribution of the MicroThermX in more than 100 countries, including Europe, Western Asia and Africa, with a market potential that exceeds $1 billion.

“Luis will be a key asset as we further penetrate the European market with KOLs and institutions,” said Sam Maravich, Vice President of International Sales and Marketing of BSD Medical. “Luis’ knowledge of the system, regulatory environments, and the numerous relationships he has built up over the years throughout Europe will be a tremendous addition to the team. This is a fantastic step forward for continued penetration of MicroThermX in the European market.”

Mr. Lopes joins BSD from IBERDATA, a Portuguese distributor of medical and hospital equipment, where he was responsible for the sales and marketing of GE Healthcare, Covidien and Ambus medical devices and systems. He has spent his entire career at IBERDATA, including serving as a regulatory affairs manager.

About the MicroThermX Microwave Ablation System

The MicroThermX is a compact, mobile, state-of-the-art, proprietary system that includes a microwave generator, single-patient-use disposable antennas, and a thermistor-based temperature monitoring system. The innovative design of the MicroThermX is the first of its kind that allows delivery of higher power levels using a single generator.

The MicroThermX utilizes innovative synchronous phased array technology that was developed and patented by MicroThermX BSD to provide a wide range of uniform zones of ablation. The MicroThermX includes innovative, high-end disposables (SynchroWave antennas) that are used in each ablation treatment and will provide a significant ongoing revenue stream.

The soft tissue (tumor) ablation world market potential is estimated to exceed $2.3 billion. The U.S. Food and Drug Administration (FDA) has granted the Company a 510(k) clearance to market the MicroThermX for ablation of soft tissue. BSD has also received CE Marking for the MicroThermX System, which allows BSD to market the MicroThermX in Europe. CE Marking is also recognized in many countries outside of the EU, providing BSD the ability to market the MicroThermX to a number of international markets.

About BSD Medical Corporation

BSD Medical Corporation develops, manufactures, markets and services systems to treat cancer and benign diseases using heat therapy, which is delivered using focused radiofrequency (RF) and microwave energy. BSD’s product lines include both hyperthermia and ablation treatment systems. BSD’s hyperthermia cancer treatment systems, which have been in use for several years in the United States, Europe and Asia, are used to treat certain tumors with heat (hyperthermia) while increasing the effectiveness of other therapies such as radiation therapy. BSD’s microwave ablation system has been developed as a stand-alone therapy to employ precision-guided microwave energy to ablate (destroy) soft tissue. The Company has developed extensive intellectual property, multiple products in the market and established distribution in the United States, Europe and Asia. Certain of the Company’s products have received regulatory approvals and clearances in the United States, Europe and China. For further information visit BSD Medical's website at www.BSDMedical.com.

Forward-Looking Statements

Statements contained in this press release that are not historical facts, including statements relating to our 2014 plans, are forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. All forward-looking statements are subject to risks and uncertainties detailed in the Company's filings with the Securities and Exchange Commission, including the market demand for our MicroThermX® products and the regulatory requirements we face. These forward-looking statements speak only as of the date on which such statements are made, and the Company undertakes no obligation to update such statements to reflect events or circumstances arising after such date, except as required by law.